

International patent application filed for novel delivery device to combat skin ageing process

- **International patent application lodged with Australian patent office for a unique transdermal skin delivery device developed in collaboration with University of Technology Sydney (UTS)**
- **Delivery device is made up of a novel family of proteins discovered through a research collaboration**
- **Recent testing results showed that treatment of human skin cells with the Company's delivery device reduces cell death to UV light exposure by up to 30% when compared to untreated cells**
- **Use of the delivery device on skin cells also highlighted protection from exposure to harsh oxidants, such as hydrogen peroxide increased cell viability by up to 20% when compared to untreated cells**
- **Patent application covers the unique transdermal delivery device, as well as the processes for preparing it and use across various applications**
- **Bod retains full ownership and rights to the intellectual property and invention including the patent application**
- **Bod actively exploring licencing opportunities for the unique delivery device**
- **Patent and product provides Bod with another unique, patent protected delivery format offering commercial and revenue optionality**

Sydney, Australia – 20 October 2022: Cannabis focused drug development and product innovation company Bod Australia Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise that it has filed an International Patent Application with the Australian Patent Office for a unique transdermal delivery device, which when applied to human skin cells can improve cell viability and serve as a UV protective barrier to help guard against the skin ageing process.

The product was discovered and developed through a collaboration commissioned by Bod alongside the University of Technology Sydney ("UTS") (refer ASX announcement: 14 August 2019). The research initiative with UTS led to the discovery that a novel family of proteins found in human cells provide antioxidant protective effects when applied to cells topically.

These proteins were found to take part in protecting cells and helping to increase both their tolerance ($P < 0.0001$) and recovery ($P < 0.01$) to UV light, along with other sources of oxidative damage when overexpressed in mammalian cells. Additional experiments have shown increased levels of antioxidant activity ($P < 0.01$), and cellular growth and metabolism ($P < 0.5$, $P < 0.01$), furthering the proteins' cellular protective effects.

Most recent results showed that treatment of human skin cells with the delivery device can reduce cell death by up to 30% when the human skin cells have been exposed to harmful levels of UV light when compared to untreated human skin cells. Further, the treatment of human skin cells with the delivery device has highlighted that the delivery device can provide the cells with protection from exposure to harsh oxidants, such as hydrogen peroxide, increasing cell viability by up to 20% when compared to untreated human skin cells

Bod has lodged the patent under the Patent Cooperation Treaty ("PCT"). The application covers the unique transdermal device, as well as describes the processes for preparing it and use across various applications.

The Company will own all rights associated with intellectual property and invention, including the patent application. This allows Bod to continue to explore licencing opportunities for the unique delivery device. The development provides Bod with another unique, delivery format offering commercial and revenue optionality. The Company will provide additional updates should full patent protection be granted.

Management commentary:

CEO Ms Jo Patterson said: *“Lodging a submission with the Australian Patent Office for this unique formulation highlights the Company’s ongoing commitment to R&D and product commercialisation. The transdermal device is the result of extensive work undertaken with UTS and has very exciting potential in the major skin care and cosmetic markets.*

“Work undertaken to date has now demonstrated that using the protein formulation on human skin cells can significantly protect against harsh skin oxidant and UV light exposure, making it applicable across a number of lucrative verticals.

“Bod will continue to work on varying combinations of the formulation. This will provide Bod with another innovative product with considerable revenue and commercial potential.”

UTS Professor of Molecular Biology (School of Life Sciences), Stella M Valenzuela added: *“Our R&D efforts with Bod commenced back in 2017 and the current patent application represents the culmination of a considerable body of scientific work. It is also very satisfying to see our research efforts lead to tangible real world outcomes that further support our initial hypotheses.*

“Ongoing test work undertaken over recent years has shown that skin cells remain healthier and more viable in instances where the delivery device containing the novel family of proteins was previously applied. This has a number of potential applications across a range of sectors and we are very excited to continue our R&D work alongside the Company to gain a further understanding of the full potential at hand.”

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis centric global life science healthcare company.

With a focus and mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, including collaborations with research partners on clinical trial programs.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538